C O M M U N I C A T I O N S
Table 1. . Predicted Partitioning of HOCl in Human Blood Plasma
by the Components of the Low MW Fraction that are Expected to
Exhibit a Significant Rate of Reaction
(M- s-1)a
1
% HOCl
component
concn (M)
k
3
′
-
-
-
-
-
-
-
7
7
Cys
Met
His
3 × 10
5 × 10
2 × 10
4 × 10
2 × 10
7 × 10
7 × 10
1 × 10
3 × 10
4 × 10
1 × 10
5 × 10
1 × 10
2 × 10
5 × 10
2 × 10
0.05%
0.01%
8
5
5
5
8
8
7
5
3
4
6
5
7
0.01%
Lys
<0.01%
<0.01%
<0.01%
<0.01%
99.93%
Trp
AA
taurine
SCN
-
-3
a
-
Value k3′ is defined in eq 4 where SCN is replaced with the
component.
of 35-55 g/L (about 750 µM). HSA bears HOCl reactive groups
(e.g., 12 Met, 2 Cys, 67 S-S).
-
-
Figure 1. Plot of keff ([SCN ]0 ) 10 mM, [OCl ]0 ) 0.1 mM, µ ) 1) as
-
-1
Experiments are underway to explore the competitiveness of the
a function of [OH ] illustrating first-order dependence. The data are fit
to the linear function: keff ) (9.85 × 10 M s )/[OH ] + 1.27 × 10
-
2
-1
-
-2
-
various components of blood plasma with respect to SCN .
-
1
s
.
-
It has been previously suggested that the SCN reaction pathway
of MPO might serve as a means of ameliorating self-destruction
by the more powerful reactant HOCl by acting as a redox buffer,
but no specific theories were advanced that explained how the
enzyme might regulate the two substrate pathways.1 The nonen-
6
-
zymic transfer of the oxidizing equivalents of HOCl to SCN that
are described here serves such a role by governing the lifetime of
the more powerful oxidant, thereby moderating the potential
autotoxicity of HOCl. Furthermore, the oxidizing equivalents of
-
22
HOCl are preserved in OSCN , a more discriminate biocide that
is not lethal to mammalian cells.
Acknowledgment. We are grateful to the PRF (35088-AC3)
and the OCAST (HR02-019) for their financial support.
Supporting Information Available: Experimental details. This
material is available free of charge via the Internet at http://pubs.acs.org.
References
(1) Hereafter, “HOCl” refers to the equilibrium mixture of HOCl and OCl-,
-
Figure 2. Concentration-time curves for HOCl (solid line) and OSCN
dashed line), with and without consideration of the k3 pathway.
about 1:1 at pH ) 7.4.
(
(
(
(
2) Podrez, E. A.; Abu-Soud, H. M.; Hazen, S. L. Free Radical Biol. Med.
2000, 28, 1717-1725.
2 2
in reality, such high concentrations of H O would deactivate MPO
3) Conese, M.; Copreni, E.; Di Gioia, S.; De Rinaldis, P.; Fumarulo, R. J.
Cystic Fibrosis 2003, 2, 129-135.
on the millisecond time scale by formation of halide-inactive
compound II.19 Nonetheless, Figure 2 clearly illustrates the redox-
4) Altman, L. C.; Baker, C.; Fleckman, P.; Luchtel, D.; Oda, D. J. Periodontal
Res. 1992, 27, 70-79.
-
buffering effect of SCN ; substantial quantities of HOCl are not
(5) Carlsson, J.; Edlund, M. B.; Haenstroem, L. Infect. Immun. 1984, 44,
581-586.
-
produced until the complete oxidation of SCN . Figure 2 also
(
6) White, W. E., Jr.; Pruitt, K. M.; Mansson-Rahemtulla, B. Antimicrob.
illustrates another significant aspect of the k
in the rate of production of OSCN over that from the k
alone. Whether this increased rate via the k
3
pathway, an increase
pathway
pathway has physi-
ological consequence remains to be demonstrated.
Agents Chemother. 1983, 23, 267-272.
-
(7) Bjoerck, L.; Claesson, O. J. Dairy Sci. 1980, 63, 919-922.
2
(
8) Marshall, V. M.; Reiter, B. J. Gen. Microbiol. 1980, 120, 513-516.
3
(9) Carlsson, J. J. Oral Path. 1987, 16, 412-416.
10) van Dalen, C. J.; Whitehouse, M. W.; Winterbourn, C. C.; Kettle, A. J.
Biochem. J. 1997, 327, 487-492.
(
-
7
-1 -1
, k ) 58 s-1, k
-1
-
4
-1 -1
We propose that the relative amounts of HOCl and OSCN that
are produced in vivo are not dictated by enzyme substrate
selectivities alone but rather by kinetic competition between the
(11) k
1
k
) 2.3 × 10
M
s
2
(Cl ) ) 2.5 × 10
M
s ,
7
(SCN ) ) 9.7 × 10 M s-1, K
-
6
-1
) 4.0 × 10 M, k ) 2.3 × 10 M
-8
-1
2
a
3
-
1
s
.
-
(12) Rate ) k [MPO-I][X
2
].
(13) Roos, D.; Winterbourn, C. C. Science 2002, 296, 669-671.
14) The bimolecular rate constant for a diffusion-controlled reaction of two
uncharged particles in water is about 8 × 10
(15) Barnett, J. J.; Stanbury, D. M. Inorg. Chem. 2002, 41, 164-166.
16) Furtmueller, P. G.; Burner, U.; Obinger, C. Biochemistry 1998, 37, 17923-
7930.
-
rate of reaction of HOCl with SCN and other reductants. While
(
physiologic fluids are very complicated and we cannot expect to
9
M
-1
s .
-1
-
accurately predict a priori whether the reaction of SCN with HOCl
(
is competitive in vivo, we can begin to probe this issue because
normal reference values are known for plasma components,20 and
1
(17) Furtmuller, P. G.; Obinger, C.; Hsuanyu, Y.; Dunford, H. B. Eur. J.
Biochem. (FEBS) 2000, 267, 5858-5864 and references therein.
the rate constants for reaction of many of these species with HOCl
are available.21 When the low molecular weight components of
human blood plasma are taken into consideration, assuming these
species are in excess with respect to HOCl and partitioning is
dictated by initial rates, we arrive at the remarkable conclusion that
(
18) This result is consistent with previous separate rate measurements of MPO-
catalyzed oxidation of Cl and SCN- and the observation that combined
-
solutions of Cl- and SCN- exhibit rates for loss of H
2
2
O that are simply
-
-
the weighted average of the individual rates for Cl and SCN for similar
concentrations (ref 10).
(
19) Jantschko, W.; Furtmuller, P. G.; Zederbauer, M.; Lanz, M.; Jakopitsch,
C.; Obinger, C. Biochem. Biophys. Res. Commun. 2003, 312, 292-298.
-
SCN would consume nearly all available HOCl (Table 1 and
(20) Duh, S.-H.; Cook, J. D. In Laboratory Reference Values, 27th ed.;
McDonough, J. T., Ed.; Williams & Wilkins: Baltimore, MD, 2000; pp
Supporting Information). However, there are many macromolecular
components of plasma that are likely to compete effectively for
HOCl. For example, human serum albumin (HSA) is the main
protein component of plasma with a normal concentration range
2074-2090.
(21) Pattison, D. I.; Davies, M. J. Chem. Res. Toxicol. 2001, 14, 1453-1464.
(22) Ashby, M. T.; Aneetha, H. J. Am. Chem. Soc. 2004, 126, 10216-10217.
JA0438361
J. AM. CHEM. SOC.
9
VOL. 126, NO. 49, 2004 15977